Since the cellular localization of β-catenin should at least in part reflect the activity of the β-catenin pathway, we examined whether β-catenin localization in lung adenocarcinoma tissues with an EGFR mutation is associated with primary resistance to gefitinib. This evidence concerns the gene EGFR and lung adenocarcinoma.